Understanding biosimilars, biologics, and the challenges surrounding their regulation and pricing in the pharmaceutical ...
The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...
While the pembrolizumab copy was eye-catching, the firm’s next big biosimilar launch in Europe is a version of Roche’s Herceptin (trastuzumab). Biosimilar companies are poised to launch ...
Biologic medicines have transformed treatment for numerous chronic and life-threatening conditions such as cancer, ...
Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).
Patients with TILs greater than or equal to 20% may safely undergo shorter trastuzumab regimens, indicating potential for treatment de-escalation. The study's limitations include non-pre-specified ...
After a phase 3 study showed a promising pCR rate with HLX11, the pertuzumab biosimilar’s BLA has been accepted for review by the FDA.
Clarity Pharmaceuticals has added 64/67Cu-SAR-trastuzumab to its Targeted Copper Theranostic (TCT) portfolio, strengthening ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results